Leadership
Isaac Eliaz
MD, MS, LAc
Chief Executive Officer
Physician and entrepreneur with 30+ years of clinical experience, Dr. Isaac Eliaz is a Gal-3 expert and inventor of the Gal-3 inhibitor. He founded Amitabha Apheresis Clinic and ecoNugenics (acquired in 2023 by a leading private equity firm). A multi-patent holder and author, Dr. Eliaz has led research in integrative medicine, developing therapies for sepsis and cancer.
Anat Stern
MSc, MBA
COO & Business Development
Business development, strategy, and operations veteran, Anat Stern has 18 years of experience in healthcare and biotechnology. She managed ecoNugenics, a nutraceutical company specializing in Galectin-3, for 7 years, leading to its successful private equity acquisition in 2023. Anat now leads ETI’s key strategic and operational efforts.
Milton Goss
BSE, MBA
CFO
Accomplished, senior accounting and financial management executive with more than 20 years of experience in the medical device, life science, and semiconductor industries. Prior to finance, worked in product development as a chemical engineer.
Bryan Knipe
MBA
Investor relations
With an MBA and 20+ years of experience in financial management, business development, and M&A, Bryan has scaled ventures across healthcare and medtech. He specializes in securing capital, go-to-market strategies, and fostering relationships for growth.
Glenn Chertow
MD, MPH
Lead Advisor Clinical Research
Expert in acute kidney failure and chronic kidney disease with more than 30 years of clinical experience. Dr. Chertow has conducted sponsored and NIH-funded trials throughout his career and maintained a research program devoted to improving kidney patient treatment.
Dale Cumming
PhD
VP of R&D
Dr. Cumming is a biotechnology expert with over 25 years of experience, including senior roles at Genetics Institute and GlycoDesign Inc., where he advanced therapeutics targeting cancer, inflammation, and infectious diseases. He co-founded Translational Medicines, Inc., and served as CSO for the International Consortium.
Susan Alpert
MD, PhD
Senior Regulatory Strategist
Dr. Alpert brings decades of regulatory expertise, including 13 years at the FDA, where she served as Director of the Office of Device Evaluation (1993-1999). She will guide ETI through FDA pathways, optimizing submissions and securing key regulatory approvals for XGal-3®.
Chelsea Newman
VP of Marketing
Chelsea specializes in scaling health, media and wellness tech ventures from seed to multi-million-dollar enterprises. She has guided both startups and large publicly traded companies to reach the hundred-million-dollar-plus range through strategic digital marketing, partnerships, and market expansion.
Ron Wald
MDCM, MPH, FRCPC
Nephrologist and Director of Hemodialysis at St. Michael's Hospital, Toronto, and a Professor of Medicine at the University of Toronto, focusing on critical care nephrology and maintenance dialysis. He led the STARRT-AKI trial on dialysis initiation in acute kidney injury and is part of the PHOSPHATE trial leadership.
Glenn M. Chertow
MD, MPH
Expert in acute kidney failure and chronic kidney disease with more than 30 years of clinical experience. Dr. Chertow has conducted sponsored and NIH-funded trials throughout his career and maintained a research program devoted to improving kidney patient treatment.
Jeffrey L. Winters
MDCM, MPH, FRCPC
Nephrologist and Director of Hemodialysis at St. Michael's Hospital, Toronto, and a Professor of Medicine at the University of Toronto, focusing on critical care nephrology and maintenance dialysis. He led the STARRT-AKI trial on dialysis initiation in acute kidney injury and is part of the PHOSPHATE trial leadership.
Patrick M. Moriarty
MD, FACC, FNLA
Director of the Atherosclerosis & Lipid Apheresis Center, Associate Professor of Internal Medicine, University of Kansas Medical Center.
Daniel Keizman
MD
Head of Genitourinary Oncology Unit at Tel Aviv Sourasky Medical Center. Highly involved in oncological clinical research, including research on Galectin 3 and prostate cancer.
David Sachs
MD
Paul S. Russell/Warner Lambert Professor of Surgery at Harvard Medical School and Director of the Transplantation Biology Research Center Laboratories at MGH. With the aim of advancing the field of transplantation science, he focuses on studying the major histocompatibility complex (MHC) and finding strategies to mitigate Graft-versus-Host Disease (GVHD).
